|Publication number||US5656016 A|
|Application number||US 08/576,821|
|Publication date||Aug 12, 1997|
|Filing date||Mar 18, 1996|
|Priority date||Mar 18, 1996|
|Also published as||CA2249572A1, EP0891203A1, WO1997034656A1|
|Publication number||08576821, 576821, US 5656016 A, US 5656016A, US-A-5656016, US5656016 A, US5656016A|
|Inventors||John E. Ogden|
|Original Assignee||Abbott Laboratories|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (6), Referenced by (157), Classifications (6), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This invention is related to sonophoretic drug delivery systems.
The majority of drugs in clinical use today are given either by injection or oral administration. Injections generally provide a fast, direct route to the bloodstream, whereas oral administration subjects the pharmaceutical agent to hepatic metabolism. Hepatic metabolism degrades the effectiveness of the pharmaceutical agents sometimes as much as 90% in some cases. The liver detoxifies drug molecules to a significant extent. As a result, a significant quantity may never reach the rest of the body due to the liver's detoxifying of the drug agent. Despite this drawback, oral administration still is the most preferred way of giving pharmaceutical drugs due to the ease of administration and the avoidance for the invasive techniques, such as injections.
Another, less common method of administration is by the use of ultrasonic vibration. An agent or drug may be driven through the skin, hair follicles, and sweat glands by the application of physical vibrations in the spectrum of KiloHertz to MegaHertz. Traditionally, there has been a great degree of variation in efficiency and modes of transfer.
There are problems associated with delivering drugs by ultrasound. For example, one obstacle is delivering an agent or drug past the skin and into the circulation where it can produce its desired effect.
The human, adult skin structure can be broken down into three layers. The stratum corneum, which is part of the epidermal layer, is the first layer of skin defense against the exterior environment. The stratum corneum is capable of absorbing superficial trauma while still maintaining adequate protection against loss of water and invasion of microorganisms and other substances. The intercellular space of the stratum corneum is approximately 30% by volume and has lipids contained within which form transport barriers.
The second layer of the epidermal layer consists of epidermal cells bound together by tight junctions into a matrix. Between the junctions lie lipid filled extracellular spaces containing a host of cellular lymphocytic factors enzymes and other antimicrobial agents. The epidermal layer is the body's prime protective barrier. Its basal cells provide metabolic and additional water barrier functions. The epidermal barrier provides a formidable defense structure even in the absence of the stratum corneum, especially to water soluble agents that do not possess a lipid extracellular phase.
The innermost layer is the dermal layer. The dermal layer consists of basil germ cells positioned upon a basil membrane. Below the basil membrane are the majority of the capillary loops that comprise the terminal states of the microcirculation tree. Penetrating all three skin layers are numerous hair follicles in various growth states. The hair follicle growth stage correlates with the death of the follicle.
WO094/08655 describes an ultrasonic transducer assembly comprising a stimulus transducer and a second transducer. The stimulus transducer creates an ultrasonic wave in the skin which causes microscopic openings through which the second transducer drives the agent through the openings. The stimuli transducer provides a first frequency from about five KiloHertz (KHz) to one MegaHertz (MHz) range for a predetermined period of time while the second transducer provides a variable frequency ultrasonic pump impulses in the MHz range. The device requires two different types of transducers and for optimal performance requires the stimulus and second transducer to be placed at an angle to each other.
There remains a need for cost-effective, improved sonophoretic systems that can deliver an agent or drug to an individual in a controlled manner.
The present invention discloses devices and methods of a sonophoretic drug delivery system for delivering an agent or a drug to an animal. The sonophoretic drug delivery system comprises a power source, a generator, at least one transducer, a transmission line, a drug delivery site, and a control system for adjusting the delivery of drug to the animal.
FIG. 1 depicts a patient wearing one embodiment of the sonophoretic drug delivery system of the present invention. The battery pack (2) includes at least one battery (4), a control system (6), and a generator (8); a wire (10); at least one transducer (12); an acoustic transmission line (14); and a reservoir (16) containing an agent or drug.
FIG. 2 depicts a schematic of one embodiment of the sonophoretic drug delivery system of the present invention having biological feedback into the control system.
FIG. 3 depicts a schematic of one embodiment of the sonophoretic drug delivery system of the present invention having thermal feedback into the control system.
The present invention comprises a sonophoretic drug delivery system using ultrasound for transdermal penetration of an agent or drugs including pharmaceuticals, proteins, vitamins, inorganic and organic compounds as well as other substances, through the skin and into the circulatory system. The sonophoretic drug delivery system comprises a power source, a control system, at least one high frequency driver such as a generator, a transmission line such as an acoustic transmission line, and at least one ultrasonic transducer. In addition, the system may comprise an agent reservoir which may be loaded with the agent or drug of choice. In yet another alternative, the system may be operated by electrical batteries thereby making the device extremely portable.
The present invention relates to devices and methods for enhancing the rate and efficacy of permeation of a drug into and through skin and into the circulatory system. The present invention utilizes ultrasound to alter the passage of the molecules through the skin and into the circulatory system.
For purposes of this disclosure, the term "agent" or "drug" may be used interchangeably. More particularly the terms include, but are not intended to be limited to, antigens, haptens, antibodies, proteins, peptides, amino acids, carbohydrates, hormones, steroids, vitamins, lipids, nucleic acids, trace elements, drugs administered for therapeutic purposes, bacterium, viruses, and metabolites.
Ultrasound frequencies used by the sonophoretic drug delivery system of the present invention can be from about 20 KiloHertz to about 300 MegaHertz with intensities of from about 0 to about 4 watts per centimeter. Preferably, the sonophoretic drug delivery system of the present invention operates at a frequency from about 1 MHz to about 300 MHz. More preferably, the sonophoretic drug delivery system of the present invention operates at a frequency from about 10 MHz to about 300 MHz.
The control system turns the ultrasonic generator on and off and adjusts the frequency to optimize the delivery of the agent or drug to the patient. The control system is a basic electronic circuit well known to those skilled in the art and can be located in a device which houses the power source and generator or it can be at a separate location on the patient.
The sonophoretic drug delivery system of the present invention may be powered by an AC source such as an electrical cord which plugs into a typical electrical outlet. More preferably, the power source will be electrical batteries. Examples of batteries which can be used with the present invention include, but are not intended to be limited to, gel cell and rechargeable alkaline cell batteries (e.g., Duracell®). A battery pack can be conveniently placed anywhere on an individual. For example, the battery pack can be conveniently placed in a clothes pocket or clipped onto a belt or other clothing. In addition, the battery pack can be small and lightweight so that the power source does not unnecessarily burden the carrier. The battery pack may also house the control system and the generator.
The power source powers the generator which typically generates a range of electrical signals which may be transmitted by a coaxial cable or other suitable wire to a transducer. As shown in FIGS. 2 and 3, the ultrasound generator propagates an electrical signal through a coaxial cable which carries the electrical impulse to the transducer. The coaxial cable is typically an insulated wire which is pliable and maneuverable. The insulated wire can be hidden under clothing if desired. The use of such coaxial cables are well known to those skilled in the art.
The generator may also comprise an amplifier to increase the input signal delivered to the transducer. For example, the amplifier receives the electrical signal from the ultrasound generator and amplifies the electrical signal. The amplified signal is then delivered to the transducer via electrodes which connect to the transducer. By applying a voltage across the electrodes, the transducer vibrates and emits ultrasonic mechanical energy. The ultrasonic mechanical energy is propagated from the transducer through the acoustic transmission line and eventually to the contact site. The use of generators is well known to those skilled in the art. Typically, the power source, control system, and generator may be housed in a single device although each may be housed separate from one another in the sonophoretic drug delivery system. The transducer may also be housed in the same device as the other components or housed separately.
The transducer may be a narrow band device such as a piezo-electric transducer. Piezo-electric transducers physically distort when stimulated by an electric charge. Connection of the transducer to an amplifier with the proper phase relationship can result in oscillations at the natural resonant frequency of the transducer (or a harmonic of it). The resonant frequency is largely determined by the dimensions of the material and its elastic modulus.
In a preferred embodiment, the transducer may be a wide-band device which is capable of vibrating in a wide range of frequencies. Some wide-band transducers can be excited by a tunable oscillator and amplifier over a wide range of frequencies. The advantage of wide-band transducers is the ability to sweep through a frequency range and operate at several frequencies. Different frequencies may be used to penetrate or move skin cells. The effect of the ultrasound on the drug may produce a "streaming" effect of agent or drug moving into the spaces between the cells and into the lower layers of the skin where it can be absorbed by the blood system. A number of different transducers are offered commercially by Ultran Transducer Company (Boalsburg, Pa.), Heat Systems Ultrasonics (Farmingdale, N.Y.), Precision Acoustic Devices (Fremont, Calif.), and Panametrics (Waltham, Mass.). "Streaming" is a phenomenon which occurs when an oscillation in a liquid or gaseous medium forces the medium molecules to move away from the source which results in a net flow of agent or drug away from the wave source. Such a phenomenon may be produced by sinusoidal and non-sinusoidal waves.
Another embodiment of the present invention includes a feedback phase-tracking loop to ensure that the frequency of the transducer matches the frequency of the amplified input signal. The feedback phase-tracking loop senses the response of the transducer to the frequency of the amplified signal and locks in on the frequency to give a maximum match. Applying an amplified signal to the transducer at a frequency other than the matched frequency may result in under-utilization of the amplified signal and its conversion to mechanical energy.
The ultrasound source can be transmitted along a fiber or rod by a transmission line such as an acoustic transmission line. The ultrasound is transmitted from the transducer along the acoustic transmission line to the drug delivery site. The drug delivery site may be either the drug reservoir or the skin/drug site where no reservoir is used. The proximal end of the transmission line is adjacent the transducer while the distal end is adjacent the drug delivery site. Acoustic transmission lines can be made of materials, such as glass fibers or polymers, which may transmit the ultrasound wave from the transducer to the site of drug delivery. The acoustic transmission line allows a remote location of the power source, control system, generator and transducer, thereby reducing the bulkiness of the system.
Yet another preferred embodiment of the present invention includes a face of the transducer having a concave surface while the other face comprises a convex surface. Simultaneous high intensity and high signal quality waves can be produced by placing a shaped ultrasound intensifier on such a geometrically focused transducer element. The intensifier abuts the concave surface of the transducer. The intensifier tapers from the concave surface to a narrow cross section. The width of the acoustic transmission line should be slightly larger than the region where the ultrasound vibrations converge. By placing a transmission line at the end of the intensifier, i.e., adjacent the narrow cross section of the intensifier or by making the acoustic transmission line an integral part of the intensifier, very high density bulk waves are propagated through the transmission line to the drug delivery site. In addition, a damping substrate may abut the convex surface of the transducer. U.S. Pat. No. 5,371,483 to Bhardwaj, hereby fully incorporated by reference, discloses such a transducer element having convex and concave faces.
An advantage of using sonophoresis to deliver drugs is that the rate and efficiency of transfer may be improved. Drugs associated with microspheres or microcapsules which would not pass through the skin and into the circulatory system may be transmitted through the skin when ultrasound is applied. By controlling the ultrasound frequency, intensity and time of exposure, the rate of transfer may be controlled.
As ultrasound is conducted via propagation of compressional waves through the skin, a coupling agent may be used with the present invention to allow for effective transmission of drug using ultrasound. Aqueous-based and oil-based coupling agents can be used with the present invention. For example, degassed water may be used as a coupling agent for transfer of mechanical energy from the device of the present invention into a patient due to the similarities in acoustic impedance between water and soft tissues. In addition, various gels and some creams are efficient coupling agents. Various aqueous based thixotropic gels are also suitable as coupling agents. Coupling agents, such as creams and thixotropic gels, are well known to those skilled in the art. The coupling agent may be loaded with substances such as antigens, haptens, antibodies, proteins, peptides, amino acids, carbohydrates, hormones, steroids, vitamins, lipids, nucleic acids, trace elements, drugs administered for therapeutic purposes, bacterium, viruses, antibodies, and metabolites.
The agent or drug to be delivered can be incorporated directly into a coupling agent or in the alternative, drug-coated or drug-loaded microcarriers may be delivered alone or incorporated into a coupling agent. The terms "microcarriers", "microspheres, and microcapsules" may be used interchangeably for the purposes of this disclosure. The terms include microcarriers which can have agent or drug bound to their surface, contained within the pores or cavities of the microcarriers, or encapsulated in a microcarrier. The rate of agent or drug release into the patient's circulatory system is controllable by the choice of microcarrier materials, such as the microcarrier's physical and chemical composition, as well as the drug's physical and chemical properties. Therapies using the sonophoretic drug delivery system of the present invention can include independently manipulating the physical and chemical compositions of both the microcarrier and the drug to optimize drug delivery.
The distal end of the transmission line relative to the transducer may contact the skin directly or indirectly. The distal end of the transmission line may contact the skin or coupling agent and/or microspheres directly where no drug reservoir is used. When a drug reservoir is used, the distal end of the transmission line may contact the drug reservoir which in turn contacts the patient's skin. The portion of the drug reservoir which contacts the patient's skin must be porous to the coupling agent and/or microcarriers upon ultrasonic stimulation from the transmission line. For sanitary purposes, it is only necessary to discard and replace the transmission line and drug reservoir when transferring the power source/control system/generator/transducer portion of the drug delivery system from one patient to another. Since the portion of the drug delivery system in contact with the patient is not transferred, such a system does not increase the risk of transferring diseases from one user to another and therefore does not require a sterilization process.
The agent or drug reservoir may be attached to the patient by a variety of means such as adhesives, tapes, synthetic and non-synthetic bands, and straps resembling wristwatch straps. For example, the reservoir may consist of an adhesive patch which contains an adhesive portion and a drug carrier portion.
The microcarriers used with the present invention can be loaded or coated with substances such as antigens, haptens, antibodies, proteins, peptides, amino acids, carbohydrates, hormones, steroids, vitamins, lipids, nucleic acids, trace elements, drugs administered for therapeutic purposes , bacterium, viruses, antibodies, and metabolites. The substances may be incorporated into microcarriers by imbedding, coating, or encapsulating the agent or drug. Upon microcarrier penetration into the dermis layer of the skin, drug release may be accomplished to produce the desired effect.
The type of release may be a factor in determining which microcarriers to use. For example, immediate versus sustained release have different requirements. If immediate release is desired, a reservoir type device encapsulated inside a film may be used (polyamide microcapsules inside a polyurethane matrix). For controlled release of bioactive substances, biodegradable or rupturable microcarriers which have penetrated the skin may be used(e.g., polyanhydride microspheres or microcapsules inside a polyanhydride matrix). The present invention is not intended to be limited to the microcarriers described herein since other microcarriers may be used as well. For example, homopolyanhydrides as described in U.S. Pat. No. 4,868,274 to Gupta, et al., hereby fully incorporated by reference, describes polyanhydrides that show an even rate of hydrolytic cleavage at different temperatures. More specifically, the homopolyanhydrides are synthesized by first forming a mixed anhydride of a desired carboxyaryloxyalkanoic acid monomer, an acid as prepolymer, and subsequently forming the homopolyanhydride by melt polycondensation of the prepolymer. The homopolyanhydrides of this invention can be mixed in the form of their melt with an agent or drug and formed into microspheres by slowly pouring the molten blend into silicone oil or other suitable oils which have been warmed to the same temperature as disclosed in Leong, et al, "Synthesis of Polyanhydrides: Melt-poly condensation, Dehydrochlorination and Dehydrative Coupling" published in Macromolecules, 20 (4), 705-712, (April, 1987), hereby fully incorporated as a reference. The homopolyanhydride in such microspheres acts as a controlled release agent for the active agent blended therewith as a result of its gradual hydrolytic cleavage under ordinary conditions.
Another embodiment of the present invention includes a biological feedback system to sense the amount of agent received by the body and control the ultrasound transmission of any further drug to be delivered. FIG. 2 depicts a schematic of the device including biological feedback. For example, a patient requiring insulin to control diabetes would have the level of blood sugar monitored and the introduction of insulin controlled to match the patient's insulin needs.
Yet another embodiment of the present invention includes a skin temperature sensor connected to the control system, as shown in FIG. 3, so as to limit the duration and amplitude of the applied ultrasound and prevent excessive temperature rise in the skin at the application site.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US5190766 *||Apr 12, 1991||Mar 2, 1993||Ken Ishihara||Method of controlling drug release by resonant sound wave|
|US5267985 *||Feb 11, 1993||Dec 7, 1993||Trancell, Inc.||Drug delivery by multiple frequency phonophoresis|
|US5350377 *||Oct 26, 1992||Sep 27, 1994||Ultrasonic Sensing & Monitoring Systems, Inc.||Medical catheter using optical fibers that transmit both laser energy and ultrasonic imaging signals|
|US5447509 *||Oct 4, 1993||Sep 5, 1995||Baxter International Inc.||Ultrasound catheter system having modulated output with feedback control|
|US5474531 *||Nov 1, 1994||Dec 12, 1995||Coraje, Inc.||Apparatus and method for enhanced intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis|
|US5556372 *||Feb 15, 1995||Sep 17, 1996||Exogen, Inc.||Apparatus for ultrasonic bone treatment|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US6024717 *||Oct 24, 1996||Feb 15, 2000||Vibrx, Inc.||Apparatus and method for sonically enhanced drug delivery|
|US6066123 *||Apr 9, 1998||May 23, 2000||The Board Of Trustees Of The Leland Stanford Junior University||Enhancement of bioavailability by use of focused energy delivery to a target tissue|
|US6231528||Jan 15, 1999||May 15, 2001||Jonathan J. Kaufman||Ultrasonic and growth factor bone-therapy: apparatus and method|
|US6234990 *||Jun 30, 1997||May 22, 2001||Sontra Medical, Inc.||Ultrasound enhancement of transdermal transport|
|US6251099||Nov 26, 1997||Jun 26, 2001||The General Hospital Corporation||Compound delivery using impulse transients|
|US6322532||Jun 10, 1999||Nov 27, 2001||3M Innovative Properties Company||Sonophoresis method and apparatus|
|US6406745||Jun 6, 2000||Jun 18, 2002||Nanosphere, Inc.||Methods for coating particles and particles produced thereby|
|US6478754||Apr 23, 2001||Nov 12, 2002||Advanced Medical Applications, Inc.||Ultrasonic method and device for wound treatment|
|US6487447||Oct 17, 2000||Nov 26, 2002||Ultra-Sonic Technologies, L.L.C.||Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation|
|US6491657||May 21, 2001||Dec 10, 2002||Sontra Medical, Inc.||Ultrasound enhancement of transdermal transport|
|US6533803||Dec 22, 2000||Mar 18, 2003||Advanced Medical Applications, Inc.||Wound treatment method and device with combination of ultrasound and laser energy|
|US6562004||Jun 5, 2000||May 13, 2003||The Massachusetts General Hospital||Transdermal delivery|
|US6575956||Nov 5, 1999||Jun 10, 2003||Pharmasonics, Inc.||Methods and apparatus for uniform transcutaneous therapeutic ultrasound|
|US6585647||Jul 21, 1999||Jul 1, 2003||Alan A. Winder||Method and means for synthetic structural imaging and volume estimation of biological tissue organs|
|US6601581||Nov 1, 2000||Aug 5, 2003||Advanced Medical Applications, Inc.||Method and device for ultrasound drug delivery|
|US6623444||Mar 21, 2001||Sep 23, 2003||Advanced Medical Applications, Inc.||Ultrasonic catheter drug delivery method and device|
|US6638249 *||Jul 17, 2000||Oct 28, 2003||Wisconsin Alumni Research Foundation||Ultrasonically actuated needle pump system|
|US6652473||Mar 21, 2001||Nov 25, 2003||Jonathan J. Kaufman||Ultrasonic and growth factor bone-therapy: apparatus and method|
|US6663554||Aug 7, 2002||Dec 16, 2003||Advanced Medical Applications, Inc.||Ultrasonic method and device for wound treatment|
|US6689094||Jun 25, 2001||Feb 10, 2004||The General Hospital Corporation||Compound delivery using impulse transients|
|US6723063||Jun 29, 1998||Apr 20, 2004||Ekos Corporation||Sheath for use with an ultrasound element|
|US6761729||Feb 14, 2003||Jul 13, 2004||Advanced Medicalapplications, Inc.||Wound treatment method and device with combination of ultrasound and laser energy|
|US6842641||Nov 25, 2002||Jan 11, 2005||Ultra-Sonic Technologies, L.L.C.||Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation|
|US6869420||Apr 29, 2004||Mar 22, 2005||Wisconsin Alumni Research Foundation||Ultrasonically actuated needle pump system|
|US6923790||May 20, 2003||Aug 2, 2005||Wisconsin Alumni Research Foundation||Ultrasonically actuated needle pump system|
|US6960173||Jan 30, 2001||Nov 1, 2005||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US6964647||Oct 6, 2000||Nov 15, 2005||Ellaz Babaev||Nozzle for ultrasound wound treatment|
|US6984404||Nov 18, 1999||Jan 10, 2006||University Of Florida Research Foundation, Inc.||Methods for preparing coated drug particles and pharmaceutical formulations thereof|
|US7063748||Mar 13, 2002||Jun 20, 2006||Nanotherapeutics, Inc.||Methods for coating particles and particles produced thereby|
|US7186246||Mar 6, 2003||Mar 6, 2007||Ekos Corporation||Ultrasound catheter with utility lumen|
|US7273458||Jan 12, 1999||Sep 25, 2007||Georgia Tech Research Corporation||Method of applying acoustic energy effective to alter transport or cell viability|
|US7332200 *||May 12, 2000||Feb 19, 2008||The General Hospital Corporation||Permeabilizing biofilms|
|US7413556||Feb 18, 2003||Aug 19, 2008||Ekos Corporation||Sheath for use with an ultrasound element|
|US7431704||Jun 7, 2006||Oct 7, 2008||Bacoustics, Llc||Apparatus and method for the treatment of tissue with ultrasound energy by direct contact|
|US7440798||May 18, 2004||Oct 21, 2008||Redding Jr Bruce K||Substance delivery system|
|US7713218||Jun 27, 2005||May 11, 2010||Celleration, Inc.||Removable applicator nozzle for ultrasound wound therapy device|
|US7727178||Dec 21, 2006||Jun 1, 2010||Ekos Corporation||Catheter with multiple ultrasound radiating members|
|US7771372||Aug 10, 2010||Ekos Corporation||Ultrasonic catheter with axial energy field|
|US7785277||Jun 23, 2006||Aug 31, 2010||Celleration, Inc.||Removable applicator nozzle for ultrasound wound therapy device|
|US7785278||Sep 18, 2007||Aug 31, 2010||Bacoustics, Llc||Apparatus and methods for debridement with ultrasound energy|
|US7785319 *||May 31, 2005||Aug 31, 2010||Microtech Medical Technologies Ltd.||Method and apparatus for treating bodily tissues with medicinal substance|
|US7789841||Sep 7, 2010||Exogen, Inc.||Method and apparatus for connective tissue treatment|
|US7828762||Dec 21, 2006||Nov 9, 2010||Ekos Corporation||Catheter with multiple ultrasound radiating members|
|US7878991||Feb 1, 2011||Bacoustics, Llc||Portable ultrasound device for the treatment of wounds|
|US7914470||Mar 29, 2011||Celleration, Inc.||Ultrasonic method and device for wound treatment|
|US7914509||Feb 15, 2007||Mar 29, 2011||Ekos Corporation||Ultrasound catheter|
|US7972286||Nov 2, 2006||Jul 5, 2011||Georgia Tech Research Corporation||Method of applying acoustic energy effective to alter transport or cell viability|
|US7976483||Dec 12, 2003||Jul 12, 2011||Ekos Corporation||Ultrasound assembly with increased efficacy|
|US8002736||Dec 19, 2008||Aug 23, 2011||Carticept Medical, Inc.||Injection systems for delivery of fluids to joints|
|US8007487||Aug 30, 2011||Carticept Medical, Inc.||Method of treating a joint using an articular injection system|
|US8010188||Nov 13, 2007||Aug 30, 2011||Kagoshima University||Drug injecting device|
|US8079976||Dec 22, 2008||Dec 20, 2011||Carticept Medical, Inc.||Articular injection system|
|US8105248 *||Oct 15, 2001||Jan 31, 2012||Orga Sense As||Medical plaster|
|US8108041||Jan 31, 2012||Zuli Holdings, Ltd.||Apparatus and method for treating body tissues with electricity or medicaments|
|US8123707||Jun 18, 2010||Feb 28, 2012||Exogen, Inc.||Method and apparatus for connective tissue treatment|
|US8142414||Mar 27, 2012||Carticept Medical, Inc.||Methods of injecting fluids into joints using a handpiece assembly|
|US8167831||Apr 16, 2010||May 1, 2012||Ekos Corporation||Catheter with multiple ultrasound radiating members|
|US8192363||Jun 5, 2012||Ekos Corporation||Catheter with multiple ultrasound radiating members|
|US8224414||Sep 13, 2005||Jul 17, 2012||Echo Therapeutics, Inc.||System and method for analyte sampling and analysis with hydrogel|
|US8226629||Mar 31, 2009||Jul 24, 2012||Ekos Corporation||Ultrasonic catheter power control|
|US8235919||Apr 7, 2003||Aug 7, 2012||Celleration, Inc.||Ultrasonic method and device for wound treatment|
|US8273361||Sep 25, 2012||Infectious Disease Research Institute||Vaccine composition containing synthetic adjuvant|
|US8287483||Mar 5, 2004||Oct 16, 2012||Echo Therapeutics, Inc.||Method and apparatus for enhancement of transdermal transport|
|US8293467||Dec 20, 2011||Oct 23, 2012||Longhorn Vaccines & Diagnostics Llc||Biological specimen collection and transport system and methods of use|
|US8343512||Oct 20, 2011||Jan 1, 2013||Infectious Disease Research Institute||Treatment of allergic conditions using a composition containing synthetic adjuvant|
|US8386027||Apr 25, 2008||Feb 26, 2013||Echo Therapeutics, Inc.||Skin permeation device for analyte sensing or transdermal drug delivery|
|US8415330||Apr 9, 2013||Longhorn Vaccines & Diagnostics, Llc||Biological specimen collection and transport system and method of use|
|US8425463||Jun 11, 2012||Apr 23, 2013||Carticept Medical, Inc.||Anesthetic injection system|
|US8425464||Jun 11, 2012||Apr 23, 2013||Carticept Medical, Inc.||Imaging-guided anesthetic injection method|
|US8491521||Jul 17, 2008||Jul 23, 2013||Celleration, Inc.||Removable multi-channel applicator nozzle|
|US8523791||Aug 11, 2009||Sep 3, 2013||Laboratoire Naturel Paris, Llc||Multi-modal drug delivery system|
|US8545440||Jun 24, 2010||Oct 1, 2013||Carticept Medical, Inc.||Injection system for delivering multiple fluids within the anatomy|
|US8562547||Apr 1, 2008||Oct 22, 2013||Eliaz Babaev||Method for debriding wounds|
|US8609114||Aug 30, 2012||Dec 17, 2013||Infectious Diesease Research Institute||Methods of using a vaccine composition containing synthetic adjuvant|
|US8669085||Jan 29, 2010||Mar 11, 2014||Ut-Battelle, Llc||Transformation of gram positive bacteria by sonoporation|
|US8669240||Mar 19, 2013||Mar 11, 2014||Longhorn Vaccines & Diagnostics, Llc||Biological specimen collection and transport system and method of use|
|US8690818||Dec 21, 2011||Apr 8, 2014||Ekos Corporation||Ultrasound catheter for providing a therapeutic effect to a vessel of a body|
|US8696612||Mar 27, 2012||Apr 15, 2014||Ekos Corporation||Catheter with multiple ultrasound radiating members|
|US8722064||Jun 4, 2010||May 13, 2014||Infectious Disease Research Institute||Synthetic glucopyranosyl lipid adjuvants|
|US8764700||Dec 20, 2011||Jul 1, 2014||Ekos Corporation||Sheath for use with an ultrasound element|
|US8812071||Mar 6, 2008||Aug 19, 2014||Echo Therapeutics, Inc.||Transdermal analyte monitoring systems and methods for analyte detection|
|US8840908||Aug 30, 2012||Sep 23, 2014||Infectious Disease Research Institute||Vaccine composition containing synthetic adjuvant|
|US8852166||Jun 20, 2012||Oct 7, 2014||Ekos Corporation||Ultrasonic catheter power control|
|US8870810||Sep 13, 2012||Oct 28, 2014||Echo Therapeutics, Inc.||Method and apparatus for enhancement of transdermal transport|
|US8957047||Apr 18, 2014||Feb 17, 2015||Immune Design Corp.||GLA monotherapy for use in cancer treatment|
|US8962593||Jul 17, 2014||Feb 24, 2015||Immune Design Corp.||GLA monotherapy for use in cancer treatment|
|US9044420||Apr 6, 2012||Jun 2, 2015||Immune Design Corp.||Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses|
|US9044542||Jun 11, 2012||Jun 2, 2015||Carticept Medical, Inc.||Imaging-guided anesthesia injection systems and methods|
|US9067015||Sep 27, 2013||Jun 30, 2015||Carticept Medical, Inc.||System for injecting fluids in a subject|
|US9080204||Dec 30, 2011||Jul 14, 2015||Longhorn Vaccines And Diagnostics, Llc||Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009|
|US9102949||Apr 22, 2011||Aug 11, 2015||University Of Massachusetts||CNS targeting AAV vectors and methods of use thereof|
|US9212399||Jan 7, 2014||Dec 15, 2015||Longhorn Vaccines And Diagnostics, Llc||Biological specimen collection and transport system and method of use|
|US9272053||Apr 22, 2011||Mar 1, 2016||University Of Massachusetts||AAV-based treatment of cholesterol-related disorders|
|US9289377||Jan 26, 2012||Mar 22, 2016||Microtech Medical Technologies Ltd.||Apparatus and method for treating body tissues with electricity or medicaments|
|US9388220||Aug 29, 2014||Jul 12, 2016||Longhorn Vaccines And Diagnostics, Llc||Immunogenic compositions and methods|
|US20020103448 *||Jan 30, 2001||Aug 1, 2002||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US20020106461 *||Mar 13, 2002||Aug 8, 2002||Nanosphere, Inc.||Methods for coating particles and particles produced thereby|
|US20030078533 *||Nov 25, 2002||Apr 24, 2003||Ludwig Weimann||Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation|
|US20030153833 *||Mar 6, 2003||Aug 14, 2003||Bennett Frederick J.||Ultrasound catheter with utility lumen|
|US20030216681 *||Feb 18, 2003||Nov 20, 2003||John Zhang||Sheath for use with an ultrasound element|
|US20030226633 *||Jun 4, 2003||Dec 11, 2003||Fujitsu Limited||Method and apparatus for fabricating bonded substrate|
|US20030229331 *||Jan 10, 2003||Dec 11, 2003||Pharmasonics, Inc.||Methods and apparatus for uniform transcutaneous therapeutic ultrasound|
|US20040015122 *||Feb 18, 2003||Jan 22, 2004||John Zhang||Sheath for use with an ultrasound element|
|US20040030267 *||Oct 15, 2001||Feb 12, 2004||Birger Orten||Medical plaster|
|US20040158192 *||Feb 5, 2004||Aug 12, 2004||The General Hospital Corporation, A Massachusetts Corporation||Compound delivery using impulse transients|
|US20040204680 *||Apr 29, 2004||Oct 14, 2004||Wisconsin Alumni Research Foundation||Ultrasonically actuated needle pump system|
|US20050010112 *||Dec 12, 2003||Jan 13, 2005||Bennett Frederick J.||Ultrasound assembly with increased efficacy|
|US20050038377 *||Sep 24, 2004||Feb 17, 2005||Redding Bruce K.||Ultrasonically enhanced substance delivery system and device|
|US20050075620 *||Jan 22, 2002||Apr 7, 2005||Yoni Iger||Method and apparatus for the delivery of substances to biological components|
|US20050131359 *||May 18, 2004||Jun 16, 2005||Redding Bruce K.Jr.||Substance delivery system|
|US20050222627 *||May 31, 2005||Oct 6, 2005||Jacob Richter||Method and apparatus for treating bodily tissues with medicinal substance|
|US20050283110 *||Jul 11, 2005||Dec 22, 2005||Children's Medical Center Corporation||Ultrasound-mediated drug delivery|
|US20060015059 *||May 17, 2005||Jan 19, 2006||Redding Bruce K Jr||Substance delivery device|
|US20060058708 *||May 31, 2005||Mar 16, 2006||Gill Heart||Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue|
|US20060058710 *||Sep 22, 2005||Mar 16, 2006||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US20060075514 *||May 20, 2005||Apr 6, 2006||Flotte Thomas J||Transport across nuclear membranes by impulse transients|
|US20070073197 *||Nov 2, 2006||Mar 29, 2007||Georgia Tech Research Corporation||Assessment and control of acoustic tissue effects|
|US20070112268 *||May 3, 2006||May 17, 2007||John Zhang||Sheath for use with an ultrasound element|
|US20080004649 *||Sep 18, 2007||Jan 3, 2008||Bacoustics Llc||Apparatus and methods for debridement with ultrasound energy|
|US20080051693 *||Aug 31, 2007||Feb 28, 2008||Bacoustics Llc||Portable Ultrasound Device for the Treatment of Wounds|
|US20080131466 *||Sep 26, 2007||Jun 5, 2008||Infectious Disease Research Institute||Vaccine composition containing synthetic adjuvant|
|US20080177220 *||Jan 8, 2007||Jul 24, 2008||The Curators Of The University Of Missouri||Ultrasound-Mediated Transcleral Drug Delivery|
|US20090004145 *||Sep 16, 2008||Jan 1, 2009||Rajagopal Ramesh||Compositions and methods involving gene therapy and proteasome modulation|
|US20100049118 *||Nov 13, 2007||Feb 25, 2010||Kahoshima University||Drug injecting device|
|US20100196983 *||Jan 29, 2010||Aug 5, 2010||Ut-Battelle, Llc||Transformation of gram positive bacteria by sonoporation|
|US20110040235 *||Aug 11, 2009||Feb 17, 2011||Castel J Chris||Multi-Modal Drug Delivery System|
|US20110070290 *||Mar 24, 2011||Infectious Disease Research Institute||Vaccine composition containing synthetic adjuvant|
|CN101534895B||Nov 13, 2007||Oct 3, 2012||国立大学法人鹿儿岛大学||Drug injecting device|
|EP1060728A1 *||Nov 9, 1998||Dec 20, 2000||Miwa Science Laboratory Inc.||Ultrasonic wave irradiation apparatus|
|EP1139886A1 *||Dec 17, 1999||Oct 10, 2001||Sontra Medical, Inc.||Methods and apparatus for enhancement of transdermal transport|
|EP1311311A2 *||Aug 24, 2001||May 21, 2003||Encapsulation Systems, Inc||Ultrasonically enhanced substance delivery method|
|EP1754488A1||May 24, 2000||Feb 21, 2007||Introgen Therapeutics, Inc.||Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases|
|EP2486938A1||Sep 26, 2007||Aug 15, 2012||Infectious Disease Research Institute||Vaccine composition containing synthetic adjuvant|
|EP2623605A1||Apr 8, 2008||Aug 7, 2013||University of Florida Research Foundation, Inc.||RAAV vector compositions having tyrosine-modified capsid proteins and methods for use|
|EP2772267A2||Aug 27, 2008||Sep 3, 2014||Longhorn Vaccines & Diagnostics, LLC||Immunogenic compositions and methods|
|EP2826860A1||Apr 22, 2011||Jan 21, 2015||The University of Massachusetts||CNS targeting AAV vectors and methods of use thereof|
|WO1998023325A1 *||Nov 26, 1997||Jun 4, 1998||The General Hospital Corporation||Compound delivery using impulse transients|
|WO1999018876A1 *||Oct 9, 1998||Apr 22, 1999||Exogen, Inc.||Method and apparatus for ultrasonic treatment of carpal tunnel syndrome|
|WO1999034858A1 *||Jan 12, 1999||Jul 15, 1999||Georgia Tech Research Corporation||Assessment and control of acoustic tissue effects|
|WO2000000095A1 *||Jun 29, 1999||Jan 6, 2000||Ekos Corporation||Sheath for use with an ultrasound element|
|WO2002015961A2 *||Aug 24, 2001||Feb 28, 2002||Encapsulation Systems, Inc.||Ultrasonically enhanced substance delivery method|
|WO2002015961A3 *||Aug 24, 2001||Jan 16, 2003||Encapsulation Systems Inc||Ultrasonically enhanced substance delivery method|
|WO2002056939A2 *||Jan 18, 2002||Jul 25, 2002||Imarx Therapeutics, Inc.||Transmembrane transport apparatus and method|
|WO2002056939A3 *||Jan 18, 2002||Sep 26, 2002||Imarx Therapeutics Inc||Transmembrane transport apparatus and method|
|WO2002058530A3 *||Jan 22, 2002||Dec 4, 2003||Yoni Iger||Method and apparatus for the delivery of substances to biological components|
|WO2004052208A1 *||Dec 9, 2002||Jun 24, 2004||Redding Bruce K Jr||A wearable, portable sonic applicator for inducing the release of bioactive compounds from internal organs|
|WO2007043011A2 *||Oct 10, 2006||Apr 19, 2007||Tylerton International Inc.||Devices and method for applying vibrations to joints|
|WO2008066316A1 *||Nov 27, 2007||Jun 5, 2008||Moda Medical||Healing apparatus and clothing having the apparatus thereof|
|WO2010135714A2||May 21, 2010||Nov 25, 2010||The Methodist Hospital Research Institute||Methods for modulating adipocyte expression using microrna compositions|
|WO2010137021A2||May 27, 2010||Dec 2, 2010||Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.||Method of generating connective tissue|
|WO2010141861A1||Jun 4, 2010||Dec 9, 2010||Infectious Disease Research Institute||Synthetic glucopyranosyl lipid adjuvants|
|WO2011133890A1||Apr 22, 2011||Oct 27, 2011||University Of Massachusetts||Cns targeting aav vectors and methods of use thereof|
|WO2011133933A2||Apr 22, 2011||Oct 27, 2011||University Of Florida Research Foundation, Inc.||Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)|
|WO2014172637A1||Apr 18, 2014||Oct 23, 2014||Immune Design Corp.||Gla monotherapy for use in cancer treatment|
|WO2015112485A1||Jan 20, 2015||Jul 30, 2015||Immune Design Corp.||Compositions for use in the treatment of allergic conditions|
|WO2015187968A1 *||Jun 4, 2015||Dec 10, 2015||Sonescence, Inc.||Systems and methods for therapeutic agent delivery|
|WO2016100575A1||Dec 16, 2015||Jun 23, 2016||Board Of Regents Of The University Of Nebraska||Gene therapy for juvenile batten disease|
|U.S. Classification||601/2, 604/290, 604/22|
|Apr 10, 1996||AS||Assignment|
Owner name: ABBOTT LABORATORIES, ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OGDEN, JOHN E.;REEL/FRAME:007948/0029
Effective date: 19960326
|Dec 27, 2000||FPAY||Fee payment|
Year of fee payment: 4
|Dec 3, 2004||FPAY||Fee payment|
Year of fee payment: 8
|Jul 19, 2005||AS||Assignment|
Owner name: HOSPIRA, INC., ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:016536/0728
Effective date: 20040430
|Dec 29, 2008||FPAY||Fee payment|
Year of fee payment: 12